8 April 2008: The Board of directors of NorDiag calls for the Annual General Meeting of NorDiag ASA to be held on Wednesday 23 April 2008 at 10.30 hours at Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo. The agenda includes, in addition to ordinary general meeting items, proposed changes in the Company`s Articles of Association. It is suggested that there should be established a nomination committee, and the Company`s registration address is proposed to be changed to Oslo. Election of members to the nomination committee is a specific item on the agenda, and candidates are provided in the notice. The Board of Directors is proposed to be reelected.

Complete notice and annual report is attached.

Contact: CFO Tone Kvåle, phone 915 19576.

NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com

Link to Stock Exchange Notification with complete notice and annual report.

Link to notice in Norwegian.